Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss		Retained Earnings	Treasury Stock	Noncontrolling Interests in Subsidiaries
Beginning balance (in shares) at Dec. 31, 2023			32,488
Beginning balance at Dec. 31, 2023		$ (443,616)	$ 492	$ 452,290	$ (7,803)	[1]	$ 219,027	$ (1,123,098)	$ 15,476
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[2]	27,260					26,879		381
Other comprehensive income, net of tax		445			445	[1]
Dividends on common stock		(30,042)		64			(30,106)
Exercise of stock options (in shares)			20
Exercise of stock options		933	$ 1	932
Stock-based compensation expense		2,545		2,545
Issuance of restricted stock (in shares)			157
Issuance of restricted stock		0		(5,610)				5,610
Tax effect of restricted stock awards (in shares)			(48)
Tax effect of restricted stock awards		(3,330)		(3,330)
Distributions to noncontrolling interests		(339)							(339)
Other (in shares)			5
Other		4		(344)				348
Ending balance (in shares) at Jun. 30, 2024			32,622
Ending balance at Jun. 30, 2024		(446,140)	$ 493	446,547	(7,358)	[1]	215,800	(1,117,140)	15,518
Beginning balance (in shares) at Mar. 31, 2024			32,604
Beginning balance at Mar. 31, 2024		(446,423)	$ 493	444,793	(7,554)	[1]	218,608	(1,118,196)	15,433
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[2]	12,445					12,243		202
Other comprehensive income, net of tax		196			196	[1]
Dividends on common stock		(15,019)		32			(15,051)
Exercise of stock options (in shares)			2
Exercise of stock options		92		92
Stock-based compensation expense		2,915		2,915
Issuance of restricted stock (in shares)			16
Issuance of restricted stock		0		(900)				900
Tax effect of restricted stock awards (in shares)			(3)
Tax effect of restricted stock awards		(138)		(138)
Distributions to noncontrolling interests		(117)							(117)
Other (in shares)			3
Other		(91)		(247)				156
Ending balance (in shares) at Jun. 30, 2024			32,622
Ending balance at Jun. 30, 2024		$ (446,140)	$ 493	446,547	(7,358)	[1]	215,800	(1,117,140)	15,518
Beginning balance (in shares) at Dec. 29, 2024		32,600	32,646
Beginning balance at Dec. 29, 2024		$ (414,216)	$ 493	452,449	(8,456)	[3]	241,717	(1,115,729)	15,310
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[4]	18,962					18,753		209
Other comprehensive income, net of tax		2,489			2,489	[3]
Dividends on common stock		(30,549)		53			(30,602)
Exercise of stock options (in shares)			9
Exercise of stock options		397		397
Stock-based compensation expense		7,493		7,493
Issuance of restricted stock (in shares)			110
Issuance of restricted stock		(15)		(5,606)				5,591
Tax effect of restricted stock awards (in shares)			(27)
Tax effect of restricted stock awards		(1,208)		(1,208)
Distributions to noncontrolling interests		(276)							(276)
Other (in shares)			15
Other		$ 169		(791)				960
Ending balance (in shares) at Jun. 29, 2025		32,800	32,753
Ending balance at Jun. 29, 2025		$ (416,754)	$ 493	452,787	(5,967)	[3]	229,868	(1,109,178)	15,243
Beginning balance (in shares) at Mar. 30, 2025			32,728
Beginning balance at Mar. 30, 2025		(416,809)	$ 493	449,625	(7,540)	[3]	235,794	(1,110,306)	15,125
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[4]	9,649					9,531		118
Other comprehensive income, net of tax		1,573			1,573	[3]
Dividends on common stock		(15,433)		24			(15,457)
Exercise of stock options (in shares)			9
Exercise of stock options		397		397
Stock-based compensation expense		3,824		3,824
Issuance of restricted stock (in shares)			7
Issuance of restricted stock		(15)		(391)				376
Tax effect of restricted stock awards (in shares)			(3)
Tax effect of restricted stock awards		(88)		(88)
Distributions to noncontrolling interests		0
Other (in shares)			12
Other		$ 148		(604)				752
Ending balance (in shares) at Jun. 29, 2025		32,800	32,753
Ending balance at Jun. 29, 2025		$ (416,754)	$ 493	$ 452,787	$ (5,967)	[3]	$ 229,868	$ (1,109,178)	$ 15,243

[1] At June 30, 2024, the accumulated other comprehensive loss of $7,358 was comprised of net unrealized foreign currency translation loss of $7,784 and net unrealized gain on the interest rate swap agreements of $426.

[2] Net income to the Company for the three and six months ended June 30, 2024 excludes $91 and $190, respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.

[3] At June 29, 2025, the accumulated other comprehensive loss of $5,967 was comprised of net unrealized foreign currency translation loss of $5,485 and net unrealized loss on the interest rate swap agreements of $482.

[4] Net income to the Company for the three and six months ended June 29, 2025 excludes $22 and $52, respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.